Spain’s ICS advertised value is concentrated in medicines

Institut Català de la Salut (ICS) advertised 2309957320 EUR across 2 notices in the last 60 days, more than any other buyer in the ranked list of 8. The finding is less about the number of notices than their structure: 2289035110 EUR sits in a notice for aggregated supplies of exclusive and/or non-substitutable medicines. For businesses, that makes the notice’s scope, product eligibility and lot structure more important than the headline total. These are advertised values, not awarded values, so they show the opportunity put to the market rather than revenue secured by a supplier.

A large total rests on an aggregated medicine requirement

ICS’s advertised value is unusually concentrated within its 2 notices. The notice titled “SUBMINISTRAMENT AGREGAT DE MEDICAMENTS EXCLUSIUS I/O NO SUBSTITUÏBLES” carries 2289035110 EUR, while the buyer’s total is 2309957320 EUR. That wording points to a procurement route built around medicines that the contracting authority identifies as exclusive or not replaceable, rather than a broad catalogue of routine hospital supplies. For potential bidders, the commercial question is therefore not simply whether the total is large. It is whether the relevant products, authorisations, supply arrangements and delivery requirements fit the notice. A high advertised value is not an award, and the figures do not show how many suppliers will ultimately receive contracts.

The buyer ranking reflects aggregation, not award performance

ICS’s position among 8 ranked buyers is driven by a very large notice alongside a second notice, rather than by a high volume of separate procedures. The contrast with the Consorci de Salut i dAtenció Social de Catalunya is instructive: that buyer advertised 1920124408 EUR across 13 notices. The comparison shows why a ranking by advertised value can say more about packaging and procurement timing than about supplier success. An aggregated requirement can place a substantial addressable value in a single procedure, while repeated notices distribute value across different specifications or purchasing events. Businesses reading the figures should distinguish the authority’s estimate from the amount eventually awarded and examine whether participation is open to direct bids, lots, or later call-offs.

The mechanism determines where competition can enter

The medicine notice’s reference to exclusive or non-substitutable products matters because product substitution is part of the competitive field. Where an authority defines a requirement narrowly, businesses may need the specified authorisation, manufacturer relationship or distribution capacity before price can become decisive. Other buyers in the figures use different structures. Servicio Andaluz de Salud advertised 1569391478 EUR across 136 notices, while Fundació Institut de Recerca Biomèdica (IRB Barcelona) advertised 1588636573 EUR across 8 notices, including a 1200000000 EUR notice under a specific dynamic acquisition system contract for chemicals and biological products. A dynamic acquisition system can admit qualified suppliers over time, whereas an aggregated medicine notice may test eligibility and supply capability within its stated scope. A large notice, or a repeat appearance by a supplier, is not evidence of impropriety without award and process evidence.

Data: Otnox — live procurement intelligence across 56 markets. Basis: 4,120 distinct priced ES notices from the last 60 days, with repeated framework ceilings counted once, 2026-05-04..2026-10-31.